Comparative Analysis of Regulatory Requirements and Approval Pathways for Peptide Therapeutics: A Systematic Evaluation of USFDA and CDSCO Frameworks

Peptide therapeutics have emerged as one of the most promising classes of pharmaceutical agents, driven by advances in solid-phase peptide synthesis, recombinant DNA technology, and innovative drug delivery platforms (1). These pharmacologically active compounds, typically composed of 2–50 amino acid residues, occupy a distinctive regulatory position bridging conventional small-molecule drugs and complex biologics (2). This hybrid nature endows peptides with exceptional target specificity and favorable safety profiles, while simultaneously creating substantial regulatory complexity regarding classification, manufacturing control, and approval pathway determination (3). The therapeutic significance of peptide drugs has expanded across diabetes mellitus, oncology, cardiovascular disorders, and metabolic syndrome (4). Peptide hormone analogues such as insulin and glucagon-like peptide-1 receptor agonists have transformed long-term disease control, while peptide-based oncology agents enable receptor-specific targeting with minimized systemic toxicity (5). The global peptide therapeutics market continues to grow, supported by increasing regulatory approvals and expanding clinical pipelines (6). Despite their clinical promise, peptide therapeutics present unique regulatory challenges arising from susceptibility to enzymatic degradation, temperature sensitivity, potential aggregation, and structural heterogeneity that complicates analytical characterization (7). Unlike small-molecule drugs, peptides require advanced analytical techniques including mass spectrometry and circular dichroism to confirm primary sequence and higher-order structure (8). Conversely, although peptides share attributes with biologics, many lack post-translational modifications and complex folding patterns, creating ambiguity regarding regulatory classification as chemical drugs or biological products (9).

In the United States, the Food and Drug Administration regulates peptide therapeutics through a bifurcated system: chemically synthesized peptides under 40 amino acids generally follow New Drug Application pathways, while recombinant or complex peptides require Biologics License Applications (10). In India, the Central Drugs Standard Control Organization regulates peptides under the Drugs and Cosmetics Act, 1940, and New Drugs and Clinical Trials Rules, 2019 (8). However, CDSCO frequently applies biologic-like scrutiny based on manufacturing complexity regardless of peptide size, creating regulatory divergence from USFDA logic (11). These differences significantly influence development timelines, approval costs, and global commercialization strategies (12). The absence of harmonized classification criteria presents substantial challenges for multinational development, potentially resulting in study duplication and delayed patient access (13).

The present study systematically compares regulatory requirements and approval pathways for peptide therapeutics between USFDA and CDSCO, analyzing framework structure, technical expectations, approval mechanics, and post-approval lifecycle management to identify critical gaps and strategic recommendations for advancing global peptide therapeutic development.

MATERIALS AND METHODS

Study Design and Scope

This research was designed as a comparative, descriptive, and analytical study aimed at evaluating regulatory requirements and approval pathways for peptide therapeutics under two major regulatory jurisdictions: the United States Food and Drug Administration and India's Central Drugs Standard Control Organization. The study focused specifically on understanding similarities, differences, strengths, and limitations of these regulatory systems as they apply to peptide-based pharmaceutical products, which represent an emerging therapeutic class requiring specialized regulatory consideration due to their intermediate molecular complexity and hybrid chemical-biological nature. The research scope encompassed the entire pharmaceutical product lifecycle from preclinical development through marketing authorization and post-approval surveillance. Regulatory pathways analyzed included the Investigational New Drug application, New Drug Application, and Biologics License Application under USFDA, and corresponding Indian pathways involving Clinical Trial Application and New Drug Approval procedures. The study was non-experimental in nature and relied extensively on secondary data obtained from regulatory documents, scientific literature, and official databases.

Literature Search and Data Collection Strategy

A comprehensive and systematic literature review was conducted to gather relevant information regarding peptide therapeutics and their regulatory approval processes across both jurisdictions. The data collection process was designed to ensure inclusion of authentic, current, and high-quality sources spanning the period 2015 to 2025. Primary data sources included official regulatory guidelines, policy documents, and notifications issued by recognized authorities(14). These comprised official publications and guidance documents from USFDA and CDSCO, international regulatory guidelines issued by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), including ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), ICH Q8 (Pharmaceutical Development), ICH Q9 (Quality Risk Management), ICH Q10 (Pharmaceutical Quality System), and ICH Q11 (Development and Manufacture of Drug Substances), as well as World Health Organization Technical Report Series documents (15). These primary sources provided the most reliable and legally binding information regarding regulatory expectations for peptide drugs, including quality, safety, and efficacy requirements.

Secondary sources were employed to supplement and interpret regulatory information, including peer-reviewed research articles and review papers from scientific journals related to pharmaceutical sciences and regulatory affairs, books and academic publications, regulatory intelligence reports and white papers, and online databases including PubMed, Scopus, ScienceDirect, and Google Scholar. The inclusion of secondary sources facilitated understanding of practical challenges, industry perspectives, and evolving regulatory trends in peptide therapeutics. To maintain quality and relevance, specific inclusion and exclusion criteria were applied. Inclusion criteria comprised publications between 2015 and 2025, documents specifically related to peptide therapeutics, regulatory guidelines from recognized authorities, and articles discussing approval pathways, clinical trials, and manufacturing requirements. Exclusion criteria eliminated outdated or superseded guidelines, non-peer-reviewed or unreliable sources, and studies unrelated to regulatory frameworks.

Stepwise Methodology

A systematic stepwise approach was followed to ensure structured data collection and analysis. The first step involved identification of relevant data sources, wherein databases and regulatory platforms were identified for comprehensive coverage of both regulatory and scientific aspects. The second step employed a well-defined keyword strategy using terms including peptide therapeutics, regulatory approval pathways, USFDA approval process, CDSCO drug approval, IND, NDA, BLA, clinical trial approval India, biologics and peptide drugs, and regulatory harmonization, with Boolean operators employed to refine search results and improve relevance(16).

The third step comprised screening and selection of literature based on relevance, authenticity, and applicability to the research objectives. Abstracts and summaries were initially reviewed, followed by full-text analysis of selected documents, with only sources providing substantial and reliable information retained for the study. The fourth step involved systematic data extraction of relevant information including regulatory framework and legal basis, approval pathways, clinical trial requirements and phases, manufacturing and quality control requirements, documentation and submission format, regulatory timelines and review procedures, and post-approval obligations and pharmacovigilance requirements. The fifth step cross-verified extracted data using multiple sources to ensure accuracy and reliability, with official regulatory portals and updated guidelines referred to confirm validity. The sixth step categorized validated data into specific segments such as regulatory, technical, and procedural parameters to enable systematic comparison between USFDA and CDSCO(17).

Development of the Comparative Framework

A comprehensive and structured comparative framework was developed to systematically evaluate regulatory requirements and approval pathways for peptide therapeutics in the United States and India. The framework was designed to enable clear comparison between regulatory systems and was divided into four major categories representing critical components of the regulatory system. The regulatory and administrative framework category focused on structural, legal, and administrative aspects governing peptide therapeutic approval. The technical and quality requirements category evaluated scientific and technical requirements associated with peptide therapeutic development and approval. The approval pathway analysis category focused on the stepwise regulatory approval process. The post-approval and lifecycle management category included regulatory requirements following drug approval, focusing on pharmacovigilance, post-marketing surveillance, and lifecycle management(18).

Case Study Validation

To validate the developed comparative framework, a detailed case study approach was adopted using a representative peptide therapeutic. Insulin was selected as the model drug based on several considerations: it is a globally approved peptide therapeutic with well-established regulatory pathways in both the United States and India; extensive data is available regarding its manufacturing, quality control, and clinical studies; it is included in the World Health Organization Essential Medicines List; and it represents a benchmark molecule for peptide drug regulation due to its widespread therapeutic importance and regulatory history. (19,20)

RESULTS

Regulatory and Administrative Framework

The regulatory and administrative framework constitutes the structural backbone of drug approval processes and plays a crucial role in determining efficiency, transparency, and predictability of regulatory systems. For peptide therapeutics, this framework becomes particularly significant due to the complex nature of these molecules, which require specialized regulatory oversight, stringent documentation, and well-defined approval pathways.

Table 1 presents the comparative evaluation of regulatory and administrative parameters between CDSCO and USFDA. The United States Food and Drug Administration operates under a highly centralized and well-defined regulatory system ensuring uniformity, transparency, and consistency in decision-making. The organizational structure involves specialized centers including the Center for Drug Evaluation and Research, which regulates chemically synthesized peptide drugs categorized as pharmaceutical products, and the Center for Biologics Evaluation and Research, which oversees recombinant or biotechnology-derived peptide therapeutics classified as biologics (21). This centralized approach ensures consistent regulatory decisions, uniform implementation of guidelines, and efficient coordination between functional units, with dedicated review teams for biologics and complex therapeutics enhancing the quality and depth of scientific evaluation.

Table 1. Comparative Outcome: Regulatory and Administrative Framework for Peptide Therapeutics.(22,23)

In contrast, the Central Drugs Standard Control Organization operates under a multi-tiered framework involving central authorities, state regulatory bodies, and expert committees. While this structure allows for distributed regulatory control, it can introduce variability in decision-making, procedural delays, and inconsistencies in regulatory interpretation (24). The involvement of multiple administrative levels may affect uniformity of regulatory outcomes, particularly for complex submissions requiring specialized scientific evaluation.

The legal framework governing drug approval represents another critical area of divergence. The USFDA regulatory system is supported by well-defined legal provisions under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, which provide explicit guidance for biologics regulation including peptide therapeutics and establish clear pathways such as the Biologics License Application. This legal clarity enhances regulatory predictability and ensures applicants have a well-defined understanding of submission requirements. CDSCO relies primarily on the Drugs and Cosmetics Act, 1940, which was originally designed for conventional pharmaceutical products and does not provide specific provisions for peptide therapeutics or advanced biologics, resulting in classification ambiguity and variable interpretation (25).

Digital infrastructure represents a major differentiating factor between the two regulatory systems. USFDA has achieved high digital maturity through implementation of the Electronic Submission Gateway and mandatory electronic Common Technical Document submissions, enabling efficient document submission, automated validation, real-time tracking, and structured communication between applicants and regulators. CDSCO has made significant progress through introduction of the SUGAM portal, representing an important step toward digital transformation; however, the system currently operates as a semi-digital platform with certain processes still relying on manual intervention and offline communication, potentially resulting in delays and reduced transparency (26).

Approval timelines reflect further differences in regulatory efficiency. USFDA operates under well-defined timelines established through the Prescription Drug User Fee Act, ensuring timely review of applications and predictable approval processes supported by adequate staffing and structured review cycles. CDSCO approval timelines are more variable and may depend on factors such as application complexity, workload, and administrative procedures, introducing uncertainty for applicants and affecting strategic planning for product development and market entry (27).

Transparency and accessibility of regulatory information also distinguish the two systems. USFDA maintains high transparency by providing public access to regulatory decisions, approval reports, clinical data summaries, and safety information through integrated databases including Drugs@FDA, ClinicalTrials.gov, and the FDA Adverse Event Reporting System. This openness supports academic research, enhances industry compliance, and builds public trust. CDSCO, while improving, currently offers limited public access to detailed regulatory data, with information such as approval timelines, review status, and decision-making processes not always readily available (28).

Technical and Quality Requirements

Technical and quality requirements represent the scientific foundation of regulatory evaluation for peptide therapeutics. Unlike conventional small-molecule drugs, peptide therapeutics exhibit higher molecular complexity, structural sensitivity, and susceptibility to degradation, necessitating stringent requirements for manufacturing processes, analytical characterization, impurity profiling, and stability evaluation.

Table 2 presents the comparative evaluation of technical and quality parameters. Good Manufacturing Practice compliance demonstrates substantial differences between the two systems. USFDA enforces strict compliance with current Good Manufacturing Practice regulations under 21 CFR Parts 210 and 211, supported by routine and risk-based inspections that focus on ensuring data integrity, process control, and overall manufacturing quality. CDSCO enforces GMP requirements under Schedule M, which has been progressively updated to align with international standards such as ICH Q7; however, implementation and enforcement may vary across manufacturing facilities and regions, potentially affecting consistency in quality standards (29).

Table 2. Comparative Outcome: Technical and Quality Requirements for Peptide Therapeutics(30)

Impurity profiling is particularly critical for peptide therapeutics due to susceptibility to degradation and formation of related substances. USFDA requires comprehensive impurity profiling in accordance with ICH Q3A, ICH Q3B, and ICH M7 guidelines, including identification, qualification, and toxicological assessment of impurities along with detailed studies on impurity formation pathways and purge mechanisms. CDSCO generally relies on pharmacopoeial limits for impurity control, ensuring compliance with established standards but potentially lacking complete understanding of impurity behavior and toxicological significance (31).

Analytical method validation expectations differ substantially. USFDA requires complete validation data for all analytical methods, including accuracy, precision, specificity, linearity, and robustness parameters, ensuring reliability and reproducibility of analytical results. CDSCO accepts ICH Q2 guidelines but may allow use of pharmacopoeial methods without full validation datasets, reducing documentation burden but potentially affecting depth of analytical evaluation. Stability study requirements reveal further divergence. USFDA requires stability data across multiple climatic zones, including long-term and accelerated studies on multiple batches, supporting global distribution and ensuring product stability under diverse environmental conditions. CDSCO focuses primarily on Zone IVb conditions relevant to the Indian climate, ensuring local applicability but potentially limiting global generalization of stability data (32).

The integration of advanced quality systems represents perhaps the most significant technical divergence. USFDA strongly emphasizes Quality by Design and Quality Risk Management, requiring applicants to demonstrate scientific understanding of product and process variability with risk assessment tools such as Failure Mode and Effects Analysis commonly used to identify and mitigate potential risks. CDSCO, while recognizing these concepts, has not yet made them mandatory, and their implementation remains limited in practice, resulting in a more compliance-oriented rather than science-driven regulatory approach (33).

Approval Pathway Analysis

The approval pathway defines the systematic progression of drug candidates from preclinical development to final market authorization. For peptide therapeutics, this process requires careful evaluation due to structural complexity, biological activity, and potential immunogenicity.

Table 3 presents the comparative evaluation of approval pathway parameters. Preclinical development stages demonstrate significant differences in regulatory expectations. USFDA imposes highly structured preclinical study requirements with extensive expectations regarding study design, documentation, and compliance with Good Laboratory Practices, ensuring a robust scientific foundation before human trials (34). This includes detailed toxicological evaluation, pharmacokinetic and pharmacodynamic characterization, genotoxicity assessment, and safety pharmacology studies. CDSCO mandates essential preclinical studies including acute, sub-acute, and chronic toxicity evaluations along with pharmacokinetic and pharmacodynamic assessments conducted per Schedule Y guidelines; however, the depth of study design and reporting may vary depending on drug nature and prior available data (35).

Table 3. Comparative Outcome: Approval Pathway Analysis for Peptide Therapeutics

Clinical trial initiation procedures highlight structural differences between the two systems. The Investigational New Drug application under USFDA represents a highly organized and scientifically rigorous process wherein detailed evaluation of preclinical safety data, manufacturing information, analytical characterization, clinical trial protocols, and investigator credentials is conducted before granting permission for clinical studies. Clinical trials may begin if no regulatory objections are raised within thirty days, providing predictable timelines. The Clinical Trial Application process under CDSCO involves multiple administrative and ethical layers including CDSCO review, Ethics Committee approval, and potential Subject Expert Committee evaluation depending on drug category, which may introduce variability in approval timelines (36).

Clinical trial conduct and oversight are more stringent under USFDA, with continuous monitoring by multiple regulatory bodies including Institutional Review Boards and Data Safety Monitoring Boards, and strict adherence to Good Clinical Practice guidelines throughout all phases. CDSCO also ensures ethical compliance through clinical trial monitoring by regulatory authorities and Ethics Committees; however, the intensity and consistency of monitoring may vary across trial sites. Marketing authorization pathways reflect the highest level of regulatory divergence. USFDA's New Drug Application and Biologics License Application pathways are supported by extensive scientific evaluation and multidisciplinary review, ensuring high confidence in safety and efficacy of approved products (37). The NDA for chemically synthesized peptides contains comprehensive documentation related to quality and manufacturing data, non-clinical studies, clinical trial results, risk-benefit evaluation, and labeling information, while the BLA for recombinant peptides emphasizes biological activity, manufacturing process validation, and product consistency. CDSCO follows a similar structural approach for New Drug Approval but with comparatively less standardization in review procedures, and the approval pathway may involve flexibility depending on prior approvals for well-established drugs. Approval timelines represent a major advantage of the USFDA system. Defined timelines under the Prescription Drug User Fee Act provide predictability and facilitate strategic planning for pharmaceutical companies, with standard and priority review timelines clearly specified. CDSCO timelines, while sometimes faster due to flexibility, lack consistency and predictability, which may affect development planning and resource allocation (38).

A notable strength of the USFDA system is the presence of structured accelerated approval pathways. Fast Track Designation, Breakthrough Therapy Designation, Accelerated Approval, and Priority Review programs enable faster access to life-saving therapies addressing serious or life-threatening diseases without compromising regulatory standards for safety and effectiveness. CDSCO currently lacks such well-defined structured accelerated pathways, although case-based flexibility is occasionally applied in specific situations, potentially limiting rapid introduction of innovative therapies in the Indian market. Risk-benefit assessment is more scientifically rigorous and quantitatively driven in the USFDA framework, incorporating advanced statistical analysis, comprehensive data evaluation, and structured benefit-risk determination. CDSCO relies more on expert committee recommendations with a relatively flexible approach, providing adaptability but potentially reducing standardization in decision-making (39).

Post-Approval and Lifecycle Management

Post-approval and lifecycle management ensure pharmaceutical products continue meeting safety, efficacy, and quality standards after market authorization. For peptide therapeutics, this stage is particularly important due to susceptibility to degradation, potential immunogenicity, and sensitivity to manufacturing variations.

Table 4 presents the comparative evaluation of post-approval and lifecycle management parameters. Pharmacovigilance systems represent the foundation of post-marketing safety monitoring. USFDA operates the FDA Adverse Event Reporting System, a highly advanced and globally integrated pharmacovigilance database that enables real-time monitoring of adverse events and supports advanced signal detection using statistical and computational tools. CDSCO operates through the Pharmacovigilance Programme of India, which has significantly improved adverse drug reaction reporting since establishment but continues to face challenges related to underreporting, limited awareness among healthcare professionals, and variability in data collection infrastructure (40).

Table 4. Comparative Outcome: Post-Approval and Lifecycle Management of Peptide Therapeutics(41,42)

Adverse event reporting practices further highlight differences in regulatory enforcement. USFDA mandates strict reporting requirements for pharmaceutical companies and healthcare professionals, ensuring comprehensive and reliable safety data. CDSCO encourages reporting, but compliance may vary across regions and institutions, potentially impacting completeness of safety data and timeliness of signal detection. Post-marketing surveillance is more structured under USFDA through requirements for Phase IV clinical trials, continuous safety monitoring, risk evaluation programs, and periodic benefit-risk reassessment. CDSCO also requires post-marketing surveillance; however, implementation and enforcement may not be as consistent across all approved products. Risk management represents a key component of lifecycle control, particularly for peptide therapeutics with complex safety profiles. USFDA requires Risk Evaluation and Mitigation Strategies for certain drugs, which include measures such as restricted distribution, patient monitoring, and healthcare provider training to ensure safe use. CDSCO does not have a uniformly implemented risk management framework, although such strategies may be applied in specific cases depending on product risk profile. Lifecycle management under USFDA follows a highly structured approach integrating product development, regulatory approval, and post-marketing monitoring into a continuous process, ensuring changes in manufacturing, formulation, or quality attributes are carefully evaluated and controlled through well-defined regulatory pathways. CDSCO manages lifecycle changes on a case-by-case basis, which may lack equivalent standardization and could introduce variability in regulatory decisions (43).

+Case Study: Insulin

The case study of insulin provides practical validation of the comparative framework and demonstrates real-world application of regulatory differences between USFDA and CDSCO. Insulin, a peptide hormone consisting of amino acid chains regulating blood glucose levels, is primarily used in diabetes mellitus management and represents one of the earliest and most successful therapeutic applications of peptide hormones.

Table 5 presents the comparative evaluation of insulin regulation. Regulatory classification constitutes a fundamental difference in insulin oversight. Under USFDA, insulin is clearly regulated as a biologic under the Biologics License Application pathway, particularly following its transition from New Drug Application to BLA classification, ensuring strict regulatory control appropriate for its biological complexity. Under CDSCO, insulin is classified as a biologic or new drug depending on formulation and manufacturing process, with the classification framework less explicitly defined for peptides, potentially leading to variable regulatory interpretation(44).

Table 5. Comparative Evaluation of Insulin as a Peptide Therapeutic